Share on StockTwits

KaloBios Pharmaceuticals (NASDAQ:KBIO) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Thursday. They currently have a $2.00 target price on the stock. Zacks‘s price objective suggests a potential upside of 21.21% from the stock’s previous close.

KaloBios Pharmaceuticals (NASDAQ:KBIO) traded down 1.20% on Thursday, hitting $1.65. 177,839 shares of the company’s stock traded hands. KaloBios Pharmaceuticals has a 52 week low of $1.57 and a 52 week high of $6.55. The stock has a 50-day moving average of $2.06 and a 200-day moving average of $2.65. The company’s market cap is $54.4 million.

KaloBios Pharmaceuticals (NASDAQ:KBIO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.05. During the same quarter in the prior year, the company posted ($0.55) earnings per share. Analysts expect that KaloBios Pharmaceuticals will post $-1.33 EPS for the current fiscal year.

KaloBios Pharmaceuticals, Inc, is a United States-based company, which develops protein therapeutics.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.